Learn About Acute Myeloblastic Leukemia with Maturation

What is the definition of Acute Myeloblastic Leukemia with Maturation?
A rare, acute myeloid leukemia characterized by evidence of granulocytic maturation and more than 20% of blast cells in the bone marrow and/or peripheral blood. The maturing non-blast granulocytic cells account for greater than or equal to 10% and monocytic cells less than or equal to 20% of the bone marrow cells. Various degrees of anemia, thrombocytopenia, or pancytopenia are present. Frequent clinical manifestations include fatigue, fever, bleeding disorders, and organomegaly, especially hepatosplenomegaly.
Save information for later
Sign Up
What are the alternative names for Acute Myeloblastic Leukemia with Maturation?
  • Acute myeloblastic leukemia with maturation
  • AML M2
  • Acute myeloblastic leukemia M2
  • Acute myeloblastic leukemia type 2
  • LAM M2
Who are the top Acute Myeloblastic Leukemia with Maturation Local Doctors?
TK
Dr. Tapan M. Kadia
Oncology | Hematology Oncology | Hematology
Elite
Highly rated in
32
conditions
Oncology
Hematology Oncology
Hematology

University of Texas System

Physicians Referral Service

1515 Holcombe Blvd 
Houston, TX 77030

Tapan Kadia is an Oncologist and a Hematologist Oncology doctor in Houston, Texas. Dr. Kadia has been practicing medicine for over 21 years and is rated as an Elite doctor by MediFind in the treatment of Acute Myeloblastic Leukemia with Maturation. He is also highly rated in 32 other conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia, Myelodysplastic Syndrome MDS, Leukemia, and Acute Myeloblastic Leukemia with Maturation. He is licensed to treat patients in Texas. Dr. Kadia is currently accepting new patients.

View Profile
JL
Dr. Jeffrey E. Lancet
Hematology Oncology | Hematology | Oncology
Elite
Highly rated in
29
conditions
Hematology Oncology
Hematology
Oncology

Moffitt Cancer Center

Moffitt Cancer Center

12902 Usf Magnolia Drive 
Tampa, FL 33612

Jeffrey Lancet is a Hematologist Oncology specialist and a Hematologist in Tampa, Florida. Dr. Lancet has been practicing medicine for over 30 years and is rated as an Elite doctor by MediFind in the treatment of Acute Myeloblastic Leukemia with Maturation. He is also highly rated in 29 other conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia, Myelodysplastic Syndrome MDS, Leukemia, and Acute Myeloblastic Leukemia without Maturation. He is licensed to treat patients in Florida. Dr. Lancet is currently accepting new patients.

View Profile
 
 
 
 
Learn about our expert tiers
Learn more
MT
Dr. Martin S. Tallman
Oncology | Hematology Oncology
Elite
Highly rated in
40
conditions
Oncology
Hematology Oncology

Memorial Hematology Lymphoma Group

675 N Saint Clair St 
Chicago, IL 60611

Martin Tallman is an Oncologist and a Hematologist Oncology doctor in Chicago, Illinois. Dr. Tallman has been practicing medicine for over 42 years and is rated as an Elite doctor by MediFind in the treatment of Acute Myeloblastic Leukemia with Maturation. He is also highly rated in 40 other conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Leukemia, and Hairy Cell Leukemia. He is licensed to treat patients in Illinois. Dr. Tallman is currently accepting new patients.

View Profile
View All Doctors
What are the latest Acute Myeloblastic Leukemia with Maturation Clinical Trials?
Salsalate + Venetoclax/Decitabine for Patients With Acute Myelogenous Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease
Who is this study for: Adult patients with Acute Myeloid Leukemia
Status: Recruiting
Start Date: October 26, 2020
Intervention Type: Drug
Study Drugs: Venetoclax, Decitabine, Azacitidine, Salsalate
Phase: Phase 2
View Trial
Summary: This phase II trial studies the side effects of salsalate when added to venetoclax and decitabine or azacitidine in treating patients with acute myeloid leukemia or myelodysplasia/myeloproliferative disease that has spread to other places in the body (advanced). Drugs used in chemotherapy, such as salsalate, venetoclax, decitabine, and azacitidine work in different ways to stop the growth of cance...
Match to trials
Find the right clinical trials for you in under a minute
Get started
Randomized, Multicenter, Phase 3 Study of Azacytidine (AZA) + Venetoclax as Maintenance Therapy in Patients With AML in Remissionin Younger Adults With Favorable-risk AML in First Remission After Conventional Chemotherapy
Status: Not yet recruiting
Start Date: June 2022
Intervention Type: Drug, Other
Study Drugs: Venetoclax, Azacitidine
Phase: Phase 2/Phase 3
View Trial
Summary: This phase III trial is conducted to evaluate if azacitidine in combination with venetoclax as maintenance therapy improves relapse-free survival (RFS) for younger adults with favorable-risk acute myeloid leukemia (AML) who remained in first complete remission (CR1) following intensive consolidation.
View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center

What are the Latest Advances for Acute Myeloblastic Leukemia with Maturation?
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
Condition: Polycythemia Vera (PV)
Journal: Cancer
Treatment Used: Ruxolitinib
Number of Patients: 377
Published: April 13, 2022
View publication
Summary: Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia.
Condition: Acute Myeloid Leukemia (AML)
Journal: Nature communications
Treatment Used: Cytarabine and Mitoxantrone with Devimistat
Number of Patients: 0
Published: March 31, 2022
View publication
Summary: Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia.
Tired of the same old research?
Check Latest Advances
Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation.
Condition: High-Risk Myeloid Malignancies
Journal: Annals of hematology
Treatment Used: Single-Agent 5-Azacytidine (AZA)
Number of Patients: 185
Published: March 30, 2022
View publication
Summary: Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation.
View All Latest Advances